Xenoport More Interesting After Washed Out Expectations

Xenoport (XNPT), a small drug company with a recently-approved drug named Horizant, has a market capitalization of approximately $300m and an enterprise value of approximately $200m. Xenoport is in the business of developing “pro-drugs” – they link existing oral drugs to a transporter molecule that allows good absorption but then disassociates from the drug once it has been absorbed.

The Burrill Report submits: By Michael Fitzhugh

By Stephen Simpson:Human Genome Sciences' (HGSI) Benlysta isn't the first would-be blockbuster to disappoint investors with its initial launch, but it's one of the larger disappointments in recent memory.

By Martin Shkreli: Human Genome Sciences (Nasdaq: HGSI) has a market cap of $2.4 billion. Its main asset is Benlysta, a newly approved lupus drug. Because HGS shares half of their gross profit from Benlysta with partner GSK, it is more appropriate to think about the “Benlysta market cap” of roughly $5 billion.

Todd Johnson submits:Human Genome Sciences (HGSI) is finally coming to market with the full FDA approved medication. The company's early years hype, and later years near-death stock experience, can all be viewed in perspective.

The FDA is expected to make an approval decision this week on a drug that would mean worlds to both the lupus-suffering patient population and to the drug’s developer,

Zacks.com submits: We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $29.00.

Prohost Biotech submits:A few days before the independent FDA committee review of Human Genome Sciences’ (HGSI) systemic lupus erythematosus (SLE) drug Benlysta (belimumab), the FDA suggested that the drug has marginal efficacy and scary adverse effects.